<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271439</url>
  </required_header>
  <id_info>
    <org_study_id>REPLACE</org_study_id>
    <nct_id>NCT01271439</nct_id>
  </id_info>
  <brief_title>Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma</brief_title>
  <acronym>REPLACE</acronym>
  <official_title>A Phase II Study of Neoadjuvant Chemotherapy + IMRT Combined With Cetuximab in Advanced T Stage of Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliate Hospital of Guangxi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Shantou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate
      acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy
      in advanced T stage of nasopharyngeal carcinoma. Besides, to figure out the relationship
      between patient outcome and EGFR gene copy number, expression and mutation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 Month Complete Response Rate + Partial Response Rate</measure>
    <time_frame>3 Months</time_frame>
    <description>According to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, Complete response was defined as disappearance of all target lesions, Partial response was defined as at least a 30% reduction in the sum of the longest diameter of target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One-year locoregional control rate</measure>
    <time_frame>1 year</time_frame>
    <description>locoregional control rate: from the time when finish treatment to persistence or recurrence in the nasopharyngeal and/or cervical region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year locoregional control rate</measure>
    <time_frame>3 years</time_frame>
    <description>locoregional control rate: from the time when finish treatment to persistence or recurrence in the nasopharyngeal and/or cervical region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year disease free survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>disease free survival rate: from the time when finish treatment to first failure at any site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year disease free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>disease free survival rate: from the time when finish treatment to first failure at any site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year overall survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival rate: from the time when finish treatment to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival rate: from the time when finish treatment to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between 3 years overall survival rate and expression of EGFR</measure>
    <time_frame>3 years</time_frame>
    <description>all patients must have sufficient pretreatment tumor biopsy specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use EORTC QLQ-C30(version 3.0) and EORTC QLQ-H&amp;N35(Version 1.0) to access the quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>collect date before treatment, the week using neoadjuvant chemotherapy, every week during radiotherapy, 6 months and every year after all treatment finished.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between 3 years overall survival rate and amplification of EGFR</measure>
    <time_frame>3 years</time_frame>
    <description>all patients must have sufficient pretreatment tumor biopsy specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between 3 years overall survival rate and mutation of EGFR</measure>
    <time_frame>3 years</time_frame>
    <description>all patients must have sufficient pretreatment tumor biopsy specimens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy</description>
    <arm_group_label>cetuximab</arm_group_label>
    <other_name>C225</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of nasopharyngeal carcinoma

          -  Range from 18～69 years old

          -  T3-4，N0-2，M0 (AJCC 2009)

          -  KPS ≥ 80

          -  Nonmetastatic diseases

          -  WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L

          -  ALT or AST ＜ 1.5×ULN、bilirubin ＜ 1.5×ULN

          -  0Serum creatinine ＜ 1.5×ULN

        Exclusion Criteria:

          -  Distance metastases

          -  Previously treated (surgery，chemotherapy, radiation therapy，EGFR targeted therapy or
             immunotherapy)

          -  Second malignancy within 5 years

          -  Precious therapy with an investigational agent

          -  Uncontrolled seizure disorder or other serious neurologic disease

          -  ≥ Grade Ш allergic reaction to any drug including in this study

          -  Clinically significant cardiac or respiratory disease

          -  Creatinine clearance &lt; 30ml/min

          -  Drug or alcohol addition

          -  Do not have full capacity for civil acts

          -  Severe complication, active infection

          -  Concurrent immunotherapy or hormone therapy for other diseases

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunfeng Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>August 10, 2013</last_update_submitted>
  <last_update_submitted_qc>August 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

